Evidence map›Paper›PMID 41491268›Full record

ArticleFungal biology and biotechnology2026

How to get the most out of fungal biotechnology?

Yvonne Nygård, Vera Meyer

Abstract readEditorial
In one paragraph

Article in Fungal biology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yvonne NygårdVTT Technical Research Centre of Finland, Espoo, Finland. Yvonne.nygard@vtt.fi.ORCID http://orcid.org/0000-0001-6117-0343
Vera MeyerInstitute of Biotechnology, Chair of Applied and Molecular Microbiology, Technische Universität Berlin, Gustav-Meyer Allee 25, 13355, Berlin, Germany. vera.meyer@tu-berlin.de.ORCID http://orcid.org/0000-0002-2298-2258

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the past decades, the importance of fungal biotechnology in advancing a bioeconomy and a circular economy has been emphasized in both scientific literature, project proposals, awarded grants and social media. Filamentous fungi have been proven to provide sustainable solutions for various industrial applications, ranging from bioremediation and medicine to the production of food, feed, materials, chemicals and energy. This is where we are today, but where could tomorrow's fungal biotechnology take us? How can the seemingly infinite potential of fungal biotechnology for a circular economy become unlocked? In this editorial, we will cover some of the critical aspects that we believe are essential for the success and impact of fungal biotechnology to a future bioeconomy.

Identifiers

PMID41491268
PMCPMC12771900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.